Navigation Links
Therapix Biosciences to Ring the Nasdaq Stock Market Opening Bell on June 28
Date:6/27/2017

TEL AVIV, Israel, June 27, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix"), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based drugs, today announced that the Company will ring The Nasdaq Stock Market Opening Bell in New York, NY on Wednesday, June 28, 2017 in honor of its initial public offering (IPO) of American Depository Shares (ADSs) listed on the Nasdaq Capital Market in March 2017.

Dr. Elran Haber, Ph.D., Chief Executive Officer of Therapix, stated, "We're proud to celebrate the successful uplisting to the Nasdaq Capital Market as Therapix builds recognition in the U.S. markets to grow exposure to a broader and more diverse investor audience. As we ring the opening bell, I would also like to take this moment to acknowledge and thank the employees, investors and partners who have supported Therapix in our journey thus far. With Therapix running two U.S. clinical studies in 2017 and data on one of them to be released this year, today's celebration comes at a landmark point in our timeline."

A live webcast of The Nasdaq Stock Market Opening Bell ceremony will be available at https://livestream.com/nasdaq/live and also on the Investor Relations portion of Therapix's website at www.therapixbio.com.

Therapix began trading on the Nasdaq Capital Market on March 22, 2017, under the symbol "TRPX".

About Therapix Biosciences

Therapix Biosciences Ltd. (Nasdaq: TRPX) is a specialty clinical-stage pharmaceutical company focused on developing technologies and therapeutics based on cannabinoid pharmaceuticals. The Company's clinical pipeline assets follow a de-risked 505(b)(2) regulatory pathway benefitting from Therapix's unique proprietary formulations based on repurposing an FDA approved synthetic cannabinoid (dronabinol). Therapix's lead compound, THX-TS01, is currently in Phase 2 clinical trials for Tourette's Syndrome and the Company intends to initiate a Phase 1 clinical study of THX-ULD01 for the treatment of Mild Cognitive Impairment, for which no FDA-approved therapies currently exist. Please visit our website for more information at www.therapixbio.com.

Contacts

Josh Blacher
Chief Financial Officer
josh@therapixbio.com

Tirth Patel (investors)
Edison Group
tpatel@edisongroup.com


To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/therapix-biosciences-to-ring-the-nasdaq-stock-market-opening-bell-on-june-28-300480633.html


'/>"/>
SOURCE Therapix Biosciences Ltd
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Therapix Biosciences to Present at Upcoming Scientific and Investor Conferences in June
2. Therapix Biosciences Ltd. Announces Full Exercise of Underwriters Over-Allotment Option
3. Therapix Biosciences Ltd. Announces Closing of U.S. Initial Public Offering of American Depositary Shares; 2,000,000 American Depository Shares Priced at $6.00 per ADS
4. Therapix Biosciences Ltd. Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing
5. Therapix Biosciences Provides Portfolio Update
6. The Israeli Pharma Company Therapix, is Joined by Five Internationally Renowned Experts, From Israel and the World, in the Field of Psychiatry and Tourette
7. 3-V Biosciences to Present Data at the AACR 2017 Annual Meeting in Washington, DC
8. Avelas Biosciences to Present at Needham & Company 16th Annual Healthcare Conference
9. Pressure BioSciences, Inc. Discusses Research Market, Goals and Milestones for First Half of 2017 in New SNNLive Video Interview with StockNewsNow.com
10. Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results
11. How These Generic Drugs Stocks are Faring? -- Neurocrine Biosciences, Evoke Pharma, SCYNEXIS, and Eagle Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July 21, ... UTHR ) announced today that it will report its ... on Thursday, July 27, 2017. ... Thursday, July 27, 2017, at 9:00 a.m. Eastern Time.  ... callers dialing 1-970-315-0533.  A rebroadcast of the teleconference will ...
(Date:7/19/2017)... , July 19, 2017  Mako Medical Laboratories ... and the Military Family Assistance Fund (MFA) to bring ... to visit with their families one last time ... to coordinate the travel and logistics needed for these ... deployed soldiers and their families. We just wish we ...
(Date:7/14/2017)... It should come as no surprise to anyone that ... of a crippling opioid epidemic. According to the Center ... deaths from opiate-based medications has quadrupled, Says, Dr. David ... 2001 to 2015". During this time, the prescription rate for ... a compelling link between prescription and eventual addiction. The problem ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... ... Facing medical needs with a newborn boy this spring, Crowley Maritime ... for employees that is uncommon in American business: 12 weeks of fully paid parental ... employees as new parents. It keeps our family life more stable. I can be ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... kklaproth(at)robinsmorton(dot)com , Robins & Morton, Perkins Will, Newcomb & Boyd, Walter P ... of the new Destination Medical Building located at Mayo Clinic in Jacksonville, ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... the federal Substance Abuse and Mental Health Services Administration’s (SAMHSA) State Targeted Response ... California Department of Health Care Services, will facilitate the development of a hub ...
(Date:7/24/2017)... ... July 24, 2017 , ... The International Essential Tremor Foundation (IETF) will ... essential tremor (ET). The seminar will take place on Saturday, Aug. 26 at the ... The program will run from 9 a.m. to 12 p.m., with check-in beginning at ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... that already work hand-in-hand on an Innovation Collaboration program, have signed a five-year ... experience and cost of the care members and patients receive. The agreement also ...
Breaking Medicine News(10 mins):